Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-23.58 Million ≈ $-3.45 Million USD) by net assets (CN¥3.18 Billion ≈ $465.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300181 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Zhejiang Jolly Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zhejiang Jolly Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
0.021x |
|
Chengdu Haoneng Tech Co Ltd
SHG:603809
|
0.000x |
|
Boai NKY Pharmaceuticals Ltd
SHE:300109
|
0.038x |
|
Cheil Worldwide
KO:030000
|
0.000x |
|
Guangdong Marubi Biotechnology Co
SHG:603983
|
0.012x |
|
Lightspeed Commerce Inc
TO:LSPD
|
0.023x |
|
Sk Gas
KO:018670
|
0.070x |
|
Jiangsu Chengxing Phosph-Chemical Co Ltd
SHG:600078
|
0.150x |
Annual Cash Flow Conversion Efficiency for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see 300181 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.24 Billion ≈ $474.31 Million |
CN¥411.80 Million ≈ $60.26 Million |
0.127x | +20.59% |
| 2024-12-31 | CN¥2.82 Billion ≈ $412.57 Million |
CN¥297.05 Million ≈ $43.47 Million |
0.105x | +1.31% |
| 2023-12-31 | CN¥2.77 Billion ≈ $405.92 Million |
CN¥288.46 Million ≈ $42.21 Million |
0.104x | -9.91% |
| 2022-12-31 | CN¥2.76 Billion ≈ $403.86 Million |
CN¥318.59 Million ≈ $46.62 Million |
0.115x | -9.08% |
| 2021-12-31 | CN¥1.98 Billion ≈ $290.21 Million |
CN¥251.80 Million ≈ $36.85 Million |
0.127x | -21.95% |
| 2020-12-31 | CN¥1.72 Billion ≈ $251.61 Million |
CN¥279.69 Million ≈ $40.93 Million |
0.163x | +77.59% |
| 2019-12-31 | CN¥1.41 Billion ≈ $206.00 Million |
CN¥128.94 Million ≈ $18.87 Million |
0.092x | +62.31% |
| 2018-12-31 | CN¥1.39 Billion ≈ $203.01 Million |
CN¥78.28 Million ≈ $11.46 Million |
0.056x | +1192.59% |
| 2017-12-31 | CN¥1.49 Billion ≈ $218.09 Million |
CN¥6.51 Million ≈ $952.09K |
0.004x | -88.98% |
| 2016-12-31 | CN¥1.47 Billion ≈ $215.38 Million |
CN¥58.30 Million ≈ $8.53 Million |
0.040x | -41.45% |
| 2015-12-31 | CN¥1.44 Billion ≈ $210.07 Million |
CN¥97.13 Million ≈ $14.21 Million |
0.068x | +330.67% |
| 2014-12-31 | CN¥871.76 Million ≈ $127.57 Million |
CN¥13.70 Million ≈ $2.00 Million |
0.016x | -58.87% |
| 2013-12-31 | CN¥772.52 Million ≈ $113.04 Million |
CN¥29.50 Million ≈ $4.32 Million |
0.038x | -11.63% |
| 2012-12-31 | CN¥705.92 Million ≈ $103.30 Million |
CN¥30.51 Million ≈ $4.46 Million |
0.043x | +116.47% |
| 2011-12-31 | CN¥683.92 Million ≈ $100.08 Million |
CN¥13.65 Million ≈ $2.00 Million |
0.020x | -93.61% |
| 2010-12-31 | CN¥207.17 Million ≈ $30.32 Million |
CN¥64.78 Million ≈ $9.48 Million |
0.313x | +18.04% |
| 2009-12-31 | CN¥165.70 Million ≈ $24.25 Million |
CN¥43.89 Million ≈ $6.42 Million |
0.265x | +26.77% |
| 2008-12-31 | CN¥149.11 Million ≈ $21.82 Million |
CN¥31.16 Million ≈ $4.56 Million |
0.209x | +88.11% |
| 2007-12-31 | CN¥144.47 Million ≈ $21.14 Million |
CN¥16.05 Million ≈ $2.35 Million |
0.111x | -- |
About Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more